Sana Biotechnology, Inc. (SANA) Misses Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles up 2% after Trump rejects return to Iran ceasefire deal terms
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Ovintiv adds 41,000 acres in Permian and Montney deals
- Russia says it could strike UK military targets in response to Kyiv's use of British missiles
Sana Biotechnology (SANA) PT Raised to $15 at Citi, Opens Positive Catalyst Watch
August 9, 2024 5:01 AM EDTCiti analyst Samantha Semenkow raised the price target on Sana Biotechnology (NASDAQ: SANA) to $15.00 (from $8.00) while maintaining a Buy rating.
The analyst comments "Sana disclosed they have enrolled multiple T1D patients into the IST being conducted in Uppsala, Sweden. The... More
